PDF(Pubmed)
Abstract：
A growing body of evidence suggests that anesthetics impact the outcome of patients with cancer after surgical intervention. However, the optimal dose and underlying mechanisms of co-administered anesthetics in lung tumor therapy have been poorly studied. Here, we aimed to investigate the role of combined anesthetics propofol, sufentanil, and rocuronium in treating lung cancer using an orthogonal experimental design and to explore the optimal combination of anesthetics. First, we evaluated the effects of the three anesthetics on the proliferation and invasion of A-549 cells using Cell Counting Kit 8 and Transwell migration and invasion assays. Subsequently, we applied the orthogonal experimental design (OED) method to screen the appropriate concentrations of the combined anesthetics with the most effective antitumor activity. We found that all three agents inhibited the proliferation of A-549 cells in a dose- and time-dependent manner when applied individually or in combination, with the highest differences in the magnitude of inhibition occurring 24 h after combined drug exposure. The optimal combination of the three anesthetics that achieved the strongest reduction in cell viability was 1.4 µmol/L propofol, 2 nmol/L sufentanil, and 7.83 µmol/L rocuronium. This optimal 3-drug combination produced a more beneficial result at 24 h than either single drug. Our results provide a theoretical basis for improving the efficacy of lung tumor treatment and optimizing anesthetic strategies.
摘要：
越来越多的证据表明，麻醉药会影响手术干预后癌症患者的预后。然而,在肺部肿瘤治疗中联合使用麻醉药的最佳剂量和潜在机制研究甚少。这里,我们旨在探讨复合麻醉药异丙酚的作用，舒芬太尼,和罗库溴铵治疗肺癌采用正交试验设计，探讨麻醉药的最佳组合。首先,我们使用细胞计数试剂盒8和Transwell迁移和侵袭试验评估了三种麻醉药对A-549细胞增殖和侵袭的影响.随后，我们应用正交实验设计（OED）方法来筛选具有最有效抗肿瘤活性的联合麻醉药的合适浓度。我们发现，当单独或联合应用时，所有三种药物均以剂量和时间依赖性方式抑制A-549细胞的增殖。在联合药物暴露后24小时，抑制幅度差异最大。三种麻醉药的最佳组合是1.4μmol/L异丙酚，2nmol/L舒芬太尼，和7.83μmol/L罗库溴铵。这种最佳的3-药物组合在24小时比任一单一药物产生更有益的结果。我们的研究结果为提高肺部肿瘤治疗的疗效和优化麻醉策略提供了理论依据。
